Biostage brings Dr Wei Zhang on Board

Biostage, Inc., a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, recently announced that Dr. Wei Zhang, a faculty professor of innovation at Peking University, has been elected to its Board of Directors.

At Peking University, Dr. Zhang has led company specific business strategy programs across the world for clients such as Novartis, Nestle, IBM, Johnson & Johnson, Roche, and Marsh & McLennan, among others. Dr. Zhang was a permanent faculty member of management at China Europe International Business School (CEIBS) from 2008 to 2012 and was the founding director of CEIBS Center for Healthcare Policy and Management.

He was also a Distinguished Bing Fellow of Health Economics at RAND (US) in 2008 and has been an adjunct faculty at Peking University School of Government. Dr. Zhang received his Ph.D. in health policy from Harvard University as part of an interfaculty program between the Graduate School of Arts and Sciences, Business School, Kennedy School of Government, and Medical School; and his M.D. from Peking Union Medical College (founded by the Rockefeller Foundation in 1918).

Register as Visitor to CPhI China 2018!